Quanterix

The company said it expects its first quarter revenue to be down 10 percent to 15 percent year over year due in part to a decline in US academic sales.

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic mainstream.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.